Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of MSTT1041A in moderate to severe atopic dermatitis
2018-003429-27Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MSTT1041A with Placebo (2 arms). Primary endpoint: Percent change from baseline to Week 16 of total EASI score. Started Dec 2018; status: completed.
02
Drugs
astegolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-003429-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003429-27.